Related Experiment Videos
[Primitive neuroectodermal tumor of the kidney].
J Ellinger1, P Bastian, S Hauser
1Klinik und Poliklinik für Urologie, Rheinische Friedrich-Wilhelms Universität, Sigmund-Freud-Strasse 25, 53105, Bonn. joergellinger@web.de
Der Urologe. Ausg. A
|March 15, 2006
Summary
Primitive neuroectodermal Tumor (PNET) is a rare kidney cancer in young adults. Multimodal treatment achieved partial and complete remission in two metastatic cases, highlighting treatment efficacy.
Area of Science:
- Oncology
- Urologic Oncology
Background:
- Primitive neuroectodermal Tumor (PNET) is a rare, aggressive malignancy predominantly affecting young adults.
- Renal PNET often presents with nonspecific symptoms, leading to delayed diagnosis, frequently postoperatively.
- Diagnostic challenges include the lack of specific radiological signs.
Observation:
- PNET is characterized by specific biomarkers, including MIC2 expression, neural markers (Vimentin, S-100, Synaptophysin), and the EWS/FLI1 translocation.
- The study presents two cases of metastatic renal PNET in patients aged 28 and 39.
- Both patients presented with advanced-stage disease.
Findings:
- Multimodal treatment, encompassing radical nephrectomy, polychemotherapy (vincristine, adriamycin, cyclophosphamide, etoposide, ifosfamide), and radiation, was administered.
- One patient achieved a partial remission, while the other experienced a complete remission.
- These outcomes demonstrate the potential effectiveness of aggressive, multimodal therapeutic strategies.
Implications:
- Aggressive multimodal therapy can lead to significant remission in metastatic renal PNET.
- Early diagnosis and prompt treatment initiation are crucial for improving patient outcomes.
- Further research into PNET biomarkers and targeted therapies may enhance treatment efficacy.